It has been documented that c-Myc mediates estrogen-dependent breast cancer cell proliferation by targeting p21 and thus contributing to estrogen resistance to therapies in ERα-positive breast tumors [58]. This evidence concerns the gene CDKN1A and breast carcinoma.